White House, DOJ Ignored Federal Intel on Marijuana Diversion, Report Claims

Intelligence Reports Allegedly Sidelined

Federal agencies possess detailed diversion data from state-licensed cannabis operations, but that intelligence may not have informed the rescheduling recommendation. The claim centers on whether DEA field reports and interagency assessments documenting leakage into illicit markets reached senior policymakers at the White House Office of National Drug Control Policy and the Department of Justice.

Diversion—the flow of legally cultivated cannabis into unregulated channels—has been a persistent enforcement concern in states with mature markets. Federal task forces in California, Oregon, and Oklahoma have documented cases where licensed cultivators exceeded plant counts, diverted inventory, or supplied unlicensed distributors.

The Rescheduling Context

DEA's proposed move to Schedule III hinged on HHS's medical-utility finding, not on enforcement or diversion metrics. The Administrative Procedure Act requires the agency to consider eight factors under the Controlled Substances Act, including actual abuse, scientific evidence, and risk to public health. Diversion data would fall under "actual abuse" and "scope, duration, and significance of abuse."

If intelligence reports were available but not incorporated into the rescheduling docket, it could expose procedural vulnerabilities in the final rule. A solid administrative record is essential to withstand judicial review, industry attorneys have noted.

State-Market Leakage: Known but Unquantified

Federal and state enforcement agencies have long acknowledged diversion, but comprehensive national estimates remain elusive. California's Department of Cannabis Control has flagged unlicensed cultivation in Humboldt and Mendocino counties. Oklahoma's OMMA revoked hundreds of licenses for compliance failures tied to diversion. Oregon's liquor commission reported excess production exceeding in-state demand by an estimated 500,000 pounds annually at the market's peak.

The scale of diversion from state-licensed operations is measurable but politically inconvenient—acknowledging it complicates the narrative that regulated markets eliminate the illicit trade.

Federal prosecutors have brought cases under the Controlled Substances Act against state-licensed operators who violated plant limits or sold outside the regulated system. Those cases represent a fraction of suspected activity.

What the White House Knew

It's unclear whether ONDCP Director Rahul Gupta or Attorney General Merrick Garland reviewed diversion intelligence before endorsing the Schedule III recommendation. Neither agency has publicly addressed the claim. The White House deferred to HHS and DEA throughout the rescheduling process, emphasizing the scientific and medical basis for the decision.

If intelligence was withheld or deprioritized, it would suggest a policy preference to advance rescheduling despite enforcement concerns. That calculus isn't unusual in contested regulatory proceedings, but it invites scrutiny during the public-comment period and any subsequent litigation.

Legal and Operational Implications

Diversion data could bolster arguments from rescheduling opponents, including law-enforcement groups and abstinence-focused advocacy organizations. The National Sheriffs' Association and Smart Approaches to Marijuana have submitted comments citing enforcement challenges in legal states. If federal intelligence corroborates those claims, it strengthens the case that cannabis still poses public-health risks warranting Schedule I or II controls.

For state operators, the allegation underscores the compliance burden. Diversion remains the most politically sensitive failure mode in regulated markets. A single large-scale diversion case can shift federal enforcement posture and jeopardize statewide programs.

What Comes Next

The DEA's final rule is expected by late 2026, and the administrative record will be subject to Freedom of Information Act requests and judicial review. If diversion intelligence exists but was excluded, litigants could argue the agency failed to consider relevant factors under the APA. That procedural defect could delay or derail the rule.

Enforcement priorities will also matter. If the Biden administration or a future DOJ prioritizes diversion prosecutions, state-licensed operators will face heightened scrutiny regardless of the scheduling outcome. Compliance audits will intensify. Plant-tracking enforcement will tighten. Interagency task forces will deploy in states with documented leakage.